SCHEMBL13329189

SCHEMBL13329189

Cc1cc(NC(=O)N2CCN(c3cnn(-c4ccccc4)c(=O)c3NCc3ccccc3)CC2)ccc1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.42
▸ ALDH1A1 P00352 3/20 0.42
▸ DCTPP1 Q9H773 1/20 0.42
▸ SMN1; SMN2 Q16637 4/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ PKM P14618 1/20 0.42
▸ TRPV1 Q8NER1 2/20 0.42
▸ MEN1 O00255 3/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ POLB P06746 2/20 0.41
▸ MAPK1 P28482 2/20 0.41
▸ USP2 O75604 2/20 0.41
▸ HTT P42858 2/20 0.41
▸ HCRTR1 O43613 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ HTR1A P08908 2/20 0.41
▸ HTR1D P28221 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11943155 0.90 MAPT (0.52) MAPTALDH1A1DCTPP1SMN1; SMN2KDM4E
SCHEMBL11943257 0.84 MAPT (0.48) MAPTALDH1A1DCTPP1SMN1; SMN2KDM4E
SCHEMBL13329125 0.79 FAAH (0.48) MAPTDCTPP1SMN1; SMN2KDM4EPKM
SCHEMBL11943260 0.77 KMT2A (0.50) MAPTALDH1A1DCTPP1SMN1; SMN2MEN1
SCHEMBL11943270 0.77 MAPT (0.48) MAPTDCTPP1SMN1; SMN2KDM4EKMT2A
SCHEMBL11943382 0.76 MAPT (0.56) MAPTALDH1A1DCTPP1SMN1; SMN2KDM4E
SCHEMBL11943162 0.76 SMN1; SMN2 (0.41) MAPTALDH1A1DCTPP1SMN1; SMN2KDM4E
SCHEMBL11943214 0.75 ALDH1A1 (0.48) MAPTALDH1A1DCTPP1SMN1; SMN2KDM4E
SCHEMBL16300919 0.74 TRPV1 (0.51) MAPTDCTPP1SMN1; SMN2KDM4ETRPV1
SCHEMBL11943153 0.73 TRPV1 (0.50) MAPTDCTPP1SMN1; SMN2TRPV1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100158992-A1 PIPERAZINE-SUBSTITUTED PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS SCHERING CORPORATION (US) 2010-06-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100158992-A1 PIPERAZINE-SUBSTITUTED PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS DPM1, GMPS, MAN2A1 MAPT 3651/4885ALDH1A1 2003/4885DCTPP1 209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback